SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

Assessing the effectiveness of human papillomavirus (HPV) vaccination to prevent cervical cancer: perspectives from Germany

By Leave a Comment

J Epidemiol Community Health

February 2010 Vol 64 No 2

For approximately 2 years now, cervical cancer has been “converted” from an oncological disease to an infectious disease, which is said to be preventable by and large by two vaccines licensed in many countries. However, human papillomavirus (HPV) vaccines differ from existing others, as the former target
a condition which only in a minute fraction of infections will lead to serious consequences, but after a long(er) latency period. Furthermore, it should be kept in mind that in clinical trials, the quadrivalent vaccine was tested in fewer than 1200 girls 16 years and younger.1

Parents Warn of HPV Vaccine Dangers

By Leave a Comment

The Epoch Times

By Susanne Larsson
Epoch Times Staff
Sweden

Despite thousands of young girls’ accounts of severe side effects from Gardasil injections, the manufacturer, Merck & Co, Inc., continues to make and sell the vaccine, which is supposed to protect against cervical cancer. Now the girls’ parents warn about the vaccine on their own websites.

According to Natural News Magazine, the Food and Drug Administration (FDA) approved Gardasil for the American market in 2006, and by February 2009, more than 40 million doses had been distributed worldwide.

Gardasil is a vaccine that’s supposed to prevent cervical cancer caused by the human papilloma virus (HPV). The virus spreads through sexual intercourse or skin contact.

September 2, 2010 Approval Letter – Cervarix

By Leave a Comment

FDA – US food and Drug Administration

DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration
Rockville, MD 20852-1448

Our STN: BL 125259/98

GlaxoSmithKline Biologicals
Attention: Matthew Whitman
2301 Renaissance Boulevard
P.O. Box 61540
King of Prussia, PA 19406-2772

Dear Mr. Whitman:

We have approved your request to supplement your biologics license application for Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant, to add lymphadenopathy to the Adverse Reactions, Postmarketing Experience section of the full prescribing information.

HPV4 not associated with autoimmune conditions

By Leave a Comment

Infectious Disease News

Posted September 13, 2010

BOSTON — The quadrivalent human papillomavirus vaccine did not raise the risk for developing autoimmune conditions, according to data presented here at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.

In a study sponsored by Merck and conducted on behalf of the Gardasil Safety Team, researchers investigated the safety of the quadrivalent HPV vaccine (HPV4; Gardasil, Merck). The researchers honed in on identifying 16 prespecified rheumatologic, endocrine and neurologic or ophthalmologic autoimmune conditions.

During the post-licensure, observational study, the researchers monitored girls and women in managed care organizations who received at least one dose of HPV4 between August 2006 and March 2008. Follow-up lasted for 6 months after administration of each dose.

The researchers found 11 conditions among a random sample of girls and women who had at least a 12-month health care plan before HPV4 vaccination. Clinicians reviewed medical records to verify diagnosis and determine time of disease onset. Incidence rates for each condition were also established for vaccinated and unvaccinated participants during case identification and review.

Más mercado (y víctimas) de la vacuna VPH

By Leave a Comment

Publicado por Miguel Jara el

Spain
13 de Septiembre de 2010

La campaña para expandir la polémica vacunación contra el virus del papiloma humano toma fuerza. Hasta ahora sólo se podía vacunar a las niñas pero la Comisión Europea ha extendido su administración a mujeres de hasta 45 años.

Hay algunas cosas que llaman la atención. La primera de ellas es que antes decían que esta vacuna estaba indicada para las jóvenes que no habían iniciado relaciones sexuales ya que según un estudio realizado con una de las marcas del preparado, Gardasil, del laboratorio Merck, si la joven estaba infectada había un 44,6% de posibilidades de contraer cáncer de útero. Ahora parece que obvian este estudio. Desde la Asociación de Afectadas por la Vacuna contra el Papiloma opinan:

“Creemos que este dato no se puede obviar y todas las mujeres deberían hacerse una citología o pruebas antes de recibir la vacuna para ver si están infectadas, de lo contrario en lugar de prevenir la hipotética posibilidad de contraer cáncer de útero, incrementarían esta posibilidad en un 44,6%“.

News

Videos

Contact